CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation

GLIA

Volumn 60, Issue 9, 2012, Pages 1437-1450

  Hernangómez, Miriam ^a   Mestre, Leyre ^a   Correa, Fernando G ^a   Loría, Frida ^a   Mecha, Miriam ^a   Iñigo, Paula M ^a   Docagne, Fabian ^b   Williams, Richard O ^c   Borrell, José ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b GIP CYCERON   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CD200; CD200R; Endocannabinoids; IL 10; Multiple sclerosis; Neuroinflammation; TMEV

Indexed keywords

ANANDAMIDE; CD200 ANTIGEN; CD200 RECEPTOR; CD200 RECEPTOR 1; GAMMA INTERFERON; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE SEVERITY; MICROGLIA; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SHAM PROCEDURE; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; ARACHIDONIC ACIDS; BRAIN; CELLS, CULTURED; ENDOCANNABINOIDS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICE; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CELL SURFACE;

EID: 84864002613     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22366     Document Type: Article

References (46)

1. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. 2003. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23: 2511-2516.
2. Arévalo-Martín A, García-Ovejero D, Gómez O, Rubio-Araiz A, Navarro-Galvé B, Guaza C, Molina-Holgado E, Molina-Holgado F. 2008. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: From neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153: 216-225.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. 2001. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300-302.
4. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, Di Marzo V. 1998. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248: 515-522.
5. Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. 2005. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 20: 207-217.
6. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. 2008. CB2 receptors in the brain: Role in central immune function. Br J Pharmacol 153: 240-251.
7. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G. 2007. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 1093: 1-11.
8. Chitnis T, Imitola J, Wang YElyaman W, Chawla P, Sharuk M, Radassi K, Bronson RT, Khoury SJ. 2007. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol 170: 1695-1712.
9. Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, Di Marzo V, Guaza C. 2010. Anandamide enhances IL-10 production in activated microglia by targeting CB2 receptors: Roles of ERK1/2, JNK and NFkB. GLIA 58: 135-147.
10. Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C. 2011. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 25: 736-749.
11. Cravatt BJ, Demarest K, Patricelli M, Bracey MH, Giang FK, Martin BR, Litchman AH. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid mide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
12. Croxford JL, Miller SD. 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R-(+)-WIN552122. J Clin Invest 111: 1231-1240.
13. Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C. 2008. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets 12: 185-195.
14. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnalg H, Raine SC, Scheneider-Stock R, Nitsch R, Ullrich O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79.
15. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. 2010. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 4: 387-404.
16. Frank MG, Barrientos RM, Biedenkapp JC, Rudy JW, Watkins LR, Maier SF. 2006. mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging 27: 717-722.
17. Franklin A, Stella N. 2003. Arachidonylcyclopropylamide increases microglia cell migration through cannabinoid CB2 and abnormal cannabidiol sensitive receptors. Eur J Pharmacol 474: 195-198.
18. Gasque P, Dean YD, Mc Greal EP, Vanbeek J, Morgan BP. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49: 171-186.
19. García-Ovejero D, Arévalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, Molina-Holgado E. 2009. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33: 57-71.
20. Gorczynski RM, Chen Z, Yu K, Hu J. 2001. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol 104: 256-264.
21. + T regulatory cells. J Immunol 180: 5946-5955.
22. Hanisch UK, Kettenmann H. 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
23. Hoek RM, Ruuls SR, Murphy CA. 2000. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290: 1768-1771.
24. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. 2006. Regulation of myeloid cell function through the CD200 receptor. J Immunol 176: 191-199.
25. Koning N, Bo L, Hoek RM. 2007. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol 62: 504-514.
26. Koning N, Swaab DF, Hoek RM, Huitinga I. 2009. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggest neuron-glia and glia-glia interaction. J Neuropathol Exp Neurol 68: 159-167.
27. Lambert DM, Fowler CJ. 2005. The endocannabinoid system: Drug targets, lead compounds and potential therapeutic applications. J Med Chem 48: 5059-5087.
28. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V. 2006. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 147: 83-91.
29. Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. 2008. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28: 633-641.
30. Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. 2010. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 37: 166-176.
31. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KHG, Lynch M. 2007. CD200 ligand-receptor interaction modulates microglial activation in vivo and in vitro. A Role for IL-4. J Neurosci 27: 8309-8313.
32. Masocha W. 2009. Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and CD200 receptor gene expression in the brain. J Neuroimmunol 214: 78-82.
33. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. 2002. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269: 3771-3778.
34. Mc Mahon EJ, Bailey SL, Vanderlugt Castenada C, Waldner H, Miller SD. 2005. Epitope spreading initialtes in the CNS in two mouse models of multiple sclerosis. Nat Med 11: 335-339.
35. Mestre L, Correa F, Arévalo-Martín A, Molina-Holgado E, Valenti M, Ortar G, Di Marzo V, Guaza C. 2005. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 92: 1327-1339.
36. Meuth SG, Simon OJ, Grimm A. 2008. CNS inflammation and neuronal degeneration is agravatted by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 194: 62-69.
37. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3-kinase/Akt signaling. J Neurosci 22: 9742-9753.
38. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Correa F, Viso A, López-Rodríguez ML, Di Marzo V, Guaza C. 2005. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19: 1338-1340.
39. Rijkers ES, De Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. 2008. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 102: 173-179.
40. Romero J, Orgado JM. 2009. Cannabinoids and neurodegenerative diseases. CNS Neurol Disord Drug Targets 8: 440-450.
41. Scotter EM, Abood ME, Glass M. 2010. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160: 480-498.
42. Stella N. 2009. Endocannabinoid signaling in microglial cells. Neuropharmacology 56: 244-253.
43. Simelyte E, Criado G, Essex D, Uger RA, Feldmann M, Williams RO. 2008. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum 58: 1038-1043.
44. Walker DG, Dalsing Hernandez JE, Campbell NA, Lue L. 2009. Decreased expression of CD200 and CD200R in Alzheimer's disease: A potential mechanism for chronic inflammation. Exp Neurol 215: 5-19.
45. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN. 2000. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13: 233-242.
46. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, Mc Clanahan T, Liu MR, Brown MH, Sedgwick JD, Phillips JH, Barclay AN. 2003. Characterization of the CD200R family in mice and humans and their interactions with CD200. J Immunol 171: 3034-3036.